LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $94.57.

Several analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 0.3% during the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after purchasing an additional 4,964 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after buying an additional 6,875 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of LeMaitre Vascular by 14.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,643 shares of the medical instruments supplier’s stock worth $375,000 after acquiring an additional 695 shares during the last quarter. Janus Henderson Group PLC grew its position in LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $105.47 on Thursday. The business has a 50-day moving average of $95.80 and a 200-day moving average of $88.23. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of 57.63, a PEG ratio of 2.62 and a beta of 0.89. LeMaitre Vascular has a fifty-two week low of $52.55 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.33 earnings per share. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.